Pete Anevski, Progyny CEO
October 30, 2023 02:47 PM EDTUpdated November 6, 08:44 AM
Health Tech

Fer­til­i­ty ben­e­fits com­pa­ny Prog­y­ny shares how it han­dles start­up val­u­a­tions when look­ing for deals

Lydia Ramsey Pflanzer

Deputy Editor

(This sto­ry is from our new Health Tech newslet­ter. If you’d like to sign up, just click here.)

When Prog­y­ny went pub­lic in 2019 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times